TP53 and non-small cell lung carcinoma: Liu et al found that MDM2 T309G (rs2279744) genotypes were not related with OS and PFS in patients with advanced non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy, however, the combined analysis showed that significant shorter survival was in patients with the p53 Pro/Pro and MDM2 GG genotype [43].